Proteomics in bone research

Expert Review of Proteomics

Volumn 7, Issue 1, 2010, Pages 103-111

  Zhang, Hengwei ^a   Recker, Robert ^a   Lee, Wai Nang Paul ^b   Xiao, Gary Guishan ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Bone remodeling; Bone turnover marker; Osteoporosis; Quantitative proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATE DEPENDENT PROTEINASE; ADENYLATE KINASE; ALCOHOL DEHYDROGENASE; ALPHA ENOLASE; CHEMOKINE RECEPTOR CCR3; COLONY STIMULATING FACTOR 1; CRYSTALLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; GLUCOCORTICOID; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LIPOCORTIN 1; MINICHROMOSOME MAINTENANCE PROTEIN 7; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEROXIREDOXIN; PEROXIREDOXIN 3; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN; PYRUVATE KINASE; QUERCETIN; RANTES; RIBULOSE PHOSPHATE; RNA HELICASE; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; TUBBY PROTEIN HOMOLOG; UNCLASSIFIED DRUG;

ABSORPTIOMETRY; APOPTOSIS; BONE; BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; BONE MARROW; BONE MINERAL; BONE TURNOVER; CATALYSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; COLLAGEN DEGRADATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; FRACTURE; GLYCOLYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HYPERPARATHYROIDISM; LIPOPHILICITY; MESENCHYMAL STEM CELL; METASTASIS; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; PROTEOMICS; REVIEW; RISK FACTOR; RNA BINDING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; BONE REMODELING; HUMANS; MESENCHYMAL STEM CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PROTEOMICS;

EID: 77951650199     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.90     Document Type: Review

References (64)

1. Rodan GA. Bone mass homeostasis and bisphosphonate action. Bone 20, 1-4 (1997).
2. Raisz LG, Rodan GA. Pathogenesis of osteoporosis. Endocrinol. Metab. Clin. North Am. 32, 15-24 (2003)
3. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94, 646-650 (1993)
4. Melton LJ 3rd. How many women have osteoporosis now? J. Bone Miner. Res. 10, 175-177 (1995).
5. Advisory Group on Osteoporosis. Report. Department of Health, London, UK (1994)
6. Abbott TA 3rd, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. Clin. Ther. 18, 127-149 (1996).
7. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 289, 1508-1514 (2000).
8. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279-302 (2002).
9. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endocrinol. Metab. 90, 6323-6331 (2005).
10. Srivastava S, Weitzmann MN, Kimble RB et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J. Clin. Invest. 102, 1850-1859 (1998).
11. Teitelbaum SL. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
12. Fatayerji D, Mawer EB, Eastell R. The role of insulin-like growth factor I in age-related changes in calcium homeostasis in men. J. Clin. Endocrinol. Metab. 85, 4657-4662 (2000).
13. Seeman E. Invited review: pathogenesis of osteoporosis. J. Appl. Physiol. 95, 2142-2151 (2003).
14. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140, 3552-3561 (1999).
15. Miura M, Tanaka K, Komatsu Y et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem. Biophys. Res. Commun. 291, 987-994 (2002).
16. Selye H. On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 16, 547-558 (1932).
17. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627-1633 (1998).
18. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med. 338, 485-492 (1998).
19. Fisher JE, Rogers MJ, Halasy JM et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl Acad. Sci. USA 96, 133-138 (1999).
20. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353, 99-102 (2005).
21. Siris ES, Roodman GD. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (6th Edition). Favus MJ (Ed.). ASBMR Washington, WA, USA 320-330 (2006).
22. Mills BG, Singer FR, Weiner LP, Suffn SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin. Orthop. Relat. Res. 1(183), 303-311 (1984).
23. Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24, 45-48 (2000).
24. Thomas RJ, Guise TA, Yin JJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451-4458 (1999).
25. Yin JJ, Selander K, Chirgwin JM et al. TGF-b a signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
26. Romas E, Bakharevski O, Hards DK et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43, 821-826 (2000).
27. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764 (1997).
28. Nakashima K, Zhou X, Kunkel G et al. The novel zinc fnger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002).
29. Galindo M, Pratap J, Young DW et al. The bone-specifc expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J. Biol. Chem. 280, 20274-20285 (2005).
30. Gaur T, Lengner CJ, Hovhannisyan H et al. Canonical WNT signaling promotes osteogenesis by directly stimulating runx2 gene expression J. Biol. Chem. 280, 33132-33140 (2005).
31. Oyama M, Kozuka-Hata H, Suzuki Y, Semba K, Yamamoto T, Sugano S. Diversity of translation start sites may defne increased complexity of the human short ORFeome. Mol. Cell. Proteomics 6, 1000-1006 (2007).
32. Jimenez CR, Spijker S, de Schipper S et al. Peptidomics of a single identifed neuron reveals diversity of multiple neuropeptides with convergent actions on cellular excitability. J. Neurosci. 26, 518-529 (2006).
33. Helmerhorst EJ, Oppenheim FG. Saliva: a dynamic proteome J. Dent. Res. 86, 680-693 (2007).
34. Kiernan UA. Quantifcation of target proteins and post-translational modifcations in affnity-based proteomic approaches. Expert Rev. Proteomics 4(3), 421-428 (2007).
35. Xiao GG, Recker RR, Deng HW. Recent advances in proteomics and cancer biomarker discovery. Clin. Med. Oncol. 2, 1-10 (2008).
36. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
37. Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev. Proteomics 6(2), 115-118 (2009).
38. Kubota K, Wakabayashi K, Matsuoka T. Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affnity tags analysis with two-dimensional chromatography. Proteomics 3, 616-626 (2003).
39. Wilson R, Belluoccio D, Little CB, Fosang AJ, Bateman JF. Proteomic characterization of mouse cartilage degradation in vitro. Arthritis Rheum. 58, 3120-3131 (2008).
40. Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin. Orthop. Relat. Res. 466, 2099-2106 (2008).
41. Guo D, Tan W, Wang F et al. Proteomic analysis of human articular cartilage: identifcation of differentially expressed proteins in knee osteoarthritis. Joint Bone Spine 75, 439-444 (2008).
42. Tan X, Cai D, Wu Y et al. Comparative analysis of serum proteomes: discovery of proteins associated with osteonecrosis of the femoral head. Transl. Res. 148, 114-119 (2006).
43. Folio C, Mora MI, Zalacain M et al Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J. Proteome Res. 8(8), 3882-3888 (2009).
44. Kang JH, Park KK, Lee IS et al. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J. Proteome Res. 5, 2620-2631 (2006).
45. Cubukcuoglu Deniz G, Durdu S, Akar AR, Ozyurda U. Biotechnology and stem cell research: a glance into the future. Anadolu Kardiyol. Derg. 8, 297-302 (2008).
46. Jiang Y, Jahagirdar BN, Reinhardt RL et al Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41-49 (2002).
47. Hassan HT, El-Sheemy M. Adult bone-marrow stem cells and their potential in medicine. J. R. Soc. Med. 97, 465-471 (2004).
48. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res. Ther. 9, 204 (2007).
49. Celebi B, Elcin YM. Proteome analysis of rat bone marrow mesenchymal stem cell subcultures. J. Proteome Res. 8, 2164-2172 (2009).
50. Mareddy S, Broadbent J, Crawford R, Xiao Y Proteomic profling of distinct clonal populations of bone marrow mesenchymal stem cells J. Cell. Biochem. 106, 776-786 (2009).
51. Foster LJ, Zeemann PA, Li C, Mann M, Jensen ON, Kassem M. Differential expression profling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 23, 1367-1377 (2005).
52. Zhang L, Feng X, McDonald JM. The role of calmodulin in the regulation of osteoclastogenesis. Endocrinology 144, 4536-4543 (2003).
53. Sun HJ, Bahk YY, Choi YR et al. A proteomic analysis during serial subculture and osteogenic differentiation of human mesenchymal stem cell. J. Orthop. Res. 24, 2059-2071 (2006).
54. Spreafco A, Frediani B, Capperucci C et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics 6, 3520-3532 (2006).
55. Kim SH, Jun S, Jang HS, Lim SK. Identifcation of parathyroid hormone-regulated proteins in mouse bone marrow cells by proteomics. Biochem. Biophys. Res. Commun. 330, 423-429 (2005).
56. Xu J, Khor KA, Sui J, Zhang J, Tan TL, Chen WN. Comparative proteomics profle of osteoblasts cultured on dissimilar hydroxyapatite biomaterials: an iTRAQ-coupled 2-D LC-MS/MS analysis. Proteomics 8, 4249-4258 (2008).
57. Bennett KP, Bergeron C, Acar E et al. Proteomics reveals multiple routes to the osteogenic phenotype in mesenchymal stem cells. BMC Genomics 8, 380 (2007).
58. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308, 1472-1477 (2005).
59. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
60. + exchanger domain containing 2 and its role in osteoclast fusion. Proteomics 8, 2625-2639 (2008).
61. Czupalla C, Mansukoski H, Pursche T, Krause E, Hofack B. Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics 5, 3868-3875 (2005).
62. Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. DOI: 10.1359/jbmr.090716 (2009) (Epub ahead of print).
63. Kostenuik PJ, Nguyen HQ, McCabe J et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res. 24, 182-195 (2009).
64. Tang Y, Wu X, Lei W et al. TGF-b1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009).